Patents by Inventor Roger John Butlin
Roger John Butlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11641858Abstract: The present invention relates to compounds which are of use in the field of agriculture as fungicides.Type: GrantFiled: April 12, 2017Date of Patent: May 9, 2023Assignee: REDAG CROP PROTECTION LTD.Inventors: Christopher John Urch, Roger John Butlin, Rebecca Kathryn Booth, Stephania Christou, Victor Ceban, Victoria Elizabeth Jackson
-
Patent number: 11241013Abstract: The present invention relates to benzimidazole ethers and related compounds which are of use in the field of agriculture as fungicides.Type: GrantFiled: October 17, 2018Date of Patent: February 8, 2022Inventors: Christopher John Urch, Roger John Butlin, Stephania Christou, Rebecca Kathryn Booth
-
Patent number: 11224224Abstract: The present invention relates to 2-thiobenzimidazoles of formula (I) which are of use as fungicides.Type: GrantFiled: January 12, 2018Date of Patent: January 18, 2022Assignee: REDAG CROP PROTECTION LTD.Inventors: Christopher John Urch, Roger John Butlin, Stephania Christou, Rebecca Kathryn Booth
-
Publication number: 20210204547Abstract: The present invention relates to benzimidazole ethers and related compounds which are of use in the field of agriculture as fungicides.Type: ApplicationFiled: October 17, 2018Publication date: July 8, 2021Inventors: Christopher John URCH, Roger John BUTLIN, Stephania CHRISTOU, Rebecca Kathryn BOOTH
-
Publication number: 20210206744Abstract: The present invention relates to substituted benzimidazoles and related compounds which are of use in the field of agriculture as fungicides.Type: ApplicationFiled: October 17, 2018Publication date: July 8, 2021Inventors: Christopher John URCH, Roger John BUTLIN, Stephania CHRISTOU, Rebecca Kathryn BOOTH
-
Publication number: 20200323209Abstract: The present invention relates to compounds which are of use in the field of agriculture as fungicides.Type: ApplicationFiled: April 12, 2017Publication date: October 15, 2020Inventors: Christopher John URCH, Roger John BUTLIN, Rebecca Kathryn BOOTH, Stephania CHRISTOU, Victor CEBAN, Victoria Elizabeth JACKSON
-
Publication number: 20200085053Abstract: The present invention relates to 2-thiobenzimidazoles of formula (I) which are of use as fungicides.Type: ApplicationFiled: January 12, 2018Publication date: March 19, 2020Inventors: Christopher John URCH, Roger John BUTLIN, Stephania CHRISTOU, Rebecca Kathryn BOOTH
-
Publication number: 20120289520Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesityType: ApplicationFiled: April 25, 2012Publication date: November 15, 2012Applicant: ASTRAZENECA ABInventors: Alan Martin Birch, Roger John Butlin, Leonie Campbell, Clive Green, Andrew Leach, Michael James Waring, Paul Michael Murray, Per Olof Ryberg
-
Patent number: 8188092Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, r is 0 or 1 and X1 is linear (1-3C)alkyl; q is 0 or 1 and X2 is fluoro, chloro or (1-3C)alkyl; Y1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n is 0, 1 or 2 and Y2 is fluoro, chloro or (1-3C)alkyl; p is 0, 1 or 2 and Y3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; Z is carboxy or —CONHSO2Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally substituted by carboxy.Type: GrantFiled: June 18, 2010Date of Patent: May 29, 2012Assignee: AstraZeneca ABInventors: Alan Martin Birch, Roger John Butlin, Leonie Campbell, Clive Green, Andrew Leach, Michael James Waring, Paul Michael Murray, Per Olof Ryberg
-
Publication number: 20120115845Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.Type: ApplicationFiled: November 7, 2011Publication date: May 10, 2012Inventors: Jack McQueen ALLEN, Roger John Butlin, Clive Green, William McCoull, Graeme Richard Robb, James Matthew Wood
-
Publication number: 20120108602Abstract: DGAT-1 inhibitor compounds of formula (1), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is ?0; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or —O—; Y2 is —(CH2)r— wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or —O—; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.Type: ApplicationFiled: May 5, 2011Publication date: May 3, 2012Applicant: AstraZeneca ABInventors: Udo Andreas BAUER, Jonas Gunnar BARLIND, Petra JOHANNESSON, Jan Magnus JOHANSSON, Alexander Tobias NOESKE, Annika Ulrika PETERSSON, Alan Martin BIRCH, Roger John BUTLIN, Clive GREEN, Andrew LEACH, Ragnar HOVLAND
-
Patent number: 8143263Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.Type: GrantFiled: August 4, 2009Date of Patent: March 27, 2012Assignee: Astrazeneca ABInventors: Stuart Norman Lile Bennett, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
-
Patent number: 8084478Abstract: Compounds of formula (I), or salts thereof, which inhibit acetyl CoA (acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein R1, R2 and R3 are each independently selected from hydrogen, fluoro, chloro, cyano, trifluoromethyl, trifluoromethoxy and difluoromethoxy; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.Type: GrantFiled: May 29, 2007Date of Patent: December 27, 2011Assignee: AsstraZeneca ABInventors: Roger John Butlin, Alleyn Thomas Plowright
-
Patent number: 7994179Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is ?O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or —O—; Y2 is —(CH2)r— wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or —O—; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.Type: GrantFiled: December 19, 2008Date of Patent: August 9, 2011Assignee: AstraZeneca ABInventors: Petra Johannesson, Jan Magnus Johansson, Annika Ulrika Petersson, Alan Martin Birch, Roger John Butlin
-
Publication number: 20110124621Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.Type: ApplicationFiled: October 8, 2008Publication date: May 26, 2011Inventors: Jack McQueen Allen, Roger John Butlin, Clive Green, William Mccoull, Graeme Richard Robb, James Matthew Wood
-
Publication number: 20110092547Abstract: Compounds of formula (I), or pharmaceutically-acceptable salts and/or pro-drugs thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein n is 0 to 3; p is 0 or 1; q is 0 to 2; R1 and R2 are, for example, independently fluoro, chloro, bromo, cyano or (1-4C)alkyl; X is —O—, —S— or —NRa— wherein Ra is hydrogen or (1-4C)alkyl; RA1 and RA2 are, for example, independently hydrogen or (1-4C)alkyl; Ring A is a di-linked ring or ring system chosen from (4-6C)cycloalkane, (7-10C)bicycloalkane and (8-12C)tricycloalkane each optionally substituted, for example, by one substituent selected from (1-4C)alkyl, (1-4C)alkoxy and (1-4C)alkoxy(1-4C)alkyl; or Ring A is phenylene optionally substituted, for example, by up to four substituents selected from fluoro, chloro, bromo, cyano, (1-4C)alkyl, (1-4C)alkoxy and (1-4C)alkoxy(1-4C)alkyl; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicamentsType: ApplicationFiled: August 15, 2008Publication date: April 21, 2011Inventors: Alan Martin Birch, Roger John Butlin, Adrian Liam Gill, Samuel David Groombridge, Alleyn Thomas Plowright, Michael James Waring
-
Publication number: 20110065706Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as GPR119 modulators, methods for their therapeutic use, particularly in the treatment of obesity and diabetes mellitus, and pharmaceutical compositions containing them.Type: ApplicationFiled: September 10, 2010Publication date: March 17, 2011Applicant: AstraZeneca ABInventors: Alan Martin Birch, Roger John Butlin, David Stephen Clarke, Andrew Leach, Philip Alexander MacFaul, Charles John O'Donnell, James Stewart Scott, Paul Robert Owen Whittamore, Dan Anders Broo, Öjvind Percy Davidsson, Kjell Erik Johansson, Hanna De La Motte
-
Publication number: 20100324068Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, r is 0 or 1 and X1 is linear (1-3C)alkyl; q is 0 or 1 and X2 is fluoro, chloro or (1-3C)alkyl; Y1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n is 0, 1 or 2 and Y2 is fluoro, chloro or (1-3C)alkyl; p is 0, 1 or 2 and Y3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; Z is carboxy or —CONHSO2Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally substituted by carboxy.Type: ApplicationFiled: June 18, 2010Publication date: December 23, 2010Applicant: AstraZeneca ABInventors: Alan Martin Birch, Roger John Butlin, Leonie Campbell, Clive Green, Andrew Leach, Michael James Waring, Paul Michael Murray, Per Olof Ryberg
-
Publication number: 20100317653Abstract: Compounds of formula (I), and salts and pro-drugs thereof: wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.Type: ApplicationFiled: August 3, 2010Publication date: December 16, 2010Applicant: AstraZeneca ABInventors: Alan Martin BIRCH, Suzanne Saxon Bowker, Roger John Butlin, Craig Samuel Donald, William Mccoull, Thorsten Nowak, Alleyn Plowright
-
Patent number: 7795283Abstract: Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.Type: GrantFiled: December 9, 2005Date of Patent: September 14, 2010Assignee: AstraZeneca ABInventors: Alan Martin Birch, Suzanne Saxon Bowker, Roger John Butlin, Craig Samuel Donald, William McCoull, Thorsten Nowak, Alleyn Plowright